The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2019 | R/R CLL: combination therapy and tailored treatment
Lydia Scarfo, MD, Vita-Salute San Raffaele University, Milan, Italy, talks about the combination of ibrutinib and venetoclax and tailoring chronic lymphocytic leukemia (CLL) treatment based on response. Dr Scarfo goes on to discuss the main challenges being faced in CLL. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
